A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM10560A After S.C. Administration in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2015
At a glance
- Drugs Efpegsomatropin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
- 18 Mar 2015 According to a Hanmi Pharmaceutical media release, data from this study were presented at the Endocrine Society conference (ENDO) 2015.
- 08 Mar 2015 Results presented at The 97th Annual Meeting of the Endocrine Society.
- 17 Oct 2014 New trial record